The AlloSeq HCT is a targeted, next-generation sequencing (NGS) assay to assess the chimerism status in patients that underwent a bone marrow transplantation. It utilizes Single Nucleotide Polymorphisms to measure the amount of recipient and donor-derived DNA present in a post-transplant sample.
This brand-new application of NGS employs 200+ SNPs and has a limit of detection of 0.32%. It bundles real time PCR’s sensitivity with the convenience of using many different markers in all the samples, a perk usually reserved to STR analysis.
Library preparation takes only 3 hours and the hands-on-time is around 1 hour and a half. The assay has been validated in the MiSeq platform and up to 24 samples can be studied in each run.
The sequences can be then loaded in a software that automatically analyzes them and shows the user different quality metrics, that can be uses to assess the run, as well as the final results for each sample.
